sábado, 14 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 23, 2026

Harju Elekter Group financial results, 1-6/2026

View original at globenewswire.com
“EUR'000 ... EBITDA 2,266 4,658 -51.4% 3,905 8,523 -54.2% ... [Table header states: EUR'000]”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ongoing preparations combined with a growing order book create favourable conditions for servicing larger project volumes and supporting revenue growth and improved profitability in the coming years.

    60% confidence

  • The order book for the second half of 2026 is stronger compared to the first half.

    60% confidence

  • In Sweden, a significant portion of the order book consists of long-term projects, with execution extending through 2028.

    60% confidence

  • Developments in the Nordic and Finnish markets provide a basis for expecting a gradual improvement in market conditions.

    60% confidence

Data points we hold from this source

Harju Elekter Group · share capital11706 USD
Harju Elekter Group · total liabilities67612 USD
Harju Elekter Group · prepayments2330 USD
Harju Elekter Group · selling expenses1.9 USD
Harju Elekter Group · stock price5.40 EUR
Harju Elekter Group · total equity95155 USD
Harju Elekter Group · labour costs21.4 USD
Harju Elekter Group · revenue sweden14.1 USD
Harju Elekter Group · selling expense ratio4.8 percent
Harju Elekter Group · share premium3619 USD
Harju Elekter Group · reserves22729 USD
Harju Elekter Group · total current assets62845 USD
Harju Elekter Group · total current liabilities52332 USD
Harju Elekter Group · labour cost ratio27.7 percent
Harju Elekter Group · gross profit5128 USD
Harju Elekter Group · other noncurrent liabilities20 USD
Harju Elekter Group · operating expenses41.5 USD
Harju Elekter Group · operating margin2.6 percent
Harju Elekter Group · inventories20456 USD
Harju Elekter Group · retained earnings57101 USD
Harju Elekter Group · eps0.01 EUR
Harju Elekter Group · investment properties27488 USD
Harju Elekter Group · total assets162767 USD
Harju Elekter Group · revenue estonia10.1 USD
Harju Elekter Group · revenue finland17.9 USD
Harju Elekter Group · capex total3.9 USD
Harju Elekter Group · borrowings current20207 USD
Harju Elekter Group · administrative expense ratio7.3 percent
Harju Elekter Group · cash2911 USD
Harju Elekter Group · borrowings noncurrent15260 USD
Harju Elekter Group · ebitda3905 USD
Harju Elekter Group · gross margin12.2 percent
Harju Elekter Group · intangible assets10381 USD
Harju Elekter Group · noncurrent financial investments27223 USD
Harju Elekter Group · noncurrent receivables2 USD
Harju Elekter Group · current provisions283 USD
Harju Elekter Group · administrative expenses2.6 USD
Harju Elekter Group · ebit1111 USD
Harju Elekter Group · prepayments from customers6422 USD
Harju Elekter Group · property plant equipment34696 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Harju Elekter Group financial results, 1-6/2026 — Source | Via News | pt.VIA.NEWS